WO 2018/226901 PCT7US2018/036363
CLAIMS
1. A living tissue model device comprising:
a first liquid compartment in which a liquid composition is stored;
a second liquid compartment in which a liquid composition is stored; and
a cell layered body disposed between the first liquid compartment and the second liquid compartment, as a partition between the first and second liquid compartments,
the cell layered body including a porous membrane having a honeycomb structure, a cell layer containing a first type of cells and disposed on one face of the porous membrane, and a cell layer containing a second type of cells different from the first type and disposed on another face of the porous membrane.
2. The living tissue model device according to claim 1, wherein the first type of cells and the second type of cells are two types of cells selected from the group consisting of parenchymal cells, stromal cells, myocytes, fibroblasts, nerve cells, glial cells, endothelial cells and epithelial cells.
3. The living tissue model device according to claim 1, wherein a material of the porous membrane comprises at least one selected from the group consisting of polybutadiene, polystyrene, polycarbonate, polysulfone, polyurethane, polylactic acid, a polylactic acid-polyglycolic acid copolymer, a polylactic acid-polycaprolactone copolymer, polyethylene terephthalate, poly(glycerol sebacate), polyacrylate, polymethacrylate, polyacrylamine, polyethylene naphthalate, polyethylene succinate, polybutylene succinate, polycaprolactone, polyamide, polyimide, a polysiloxane derivative and triacetylcellulose.
4. The living tissue model device according to claim 1, wherein each surface of the porous membrane is covered by at least one selected from the group consisting of fibronectin, collagen, laminin, vitronectin, gelatin, perlecan, nidogen, proteoglycan, osteopontin, tenascin, nephronectin, a basement membrane matrix, a recombinant peptide and polylysine.
5. The living tissue model device according to claim 1, wherein an average diameter of openings of through-holes in the porous membrane is from 1 urn to 20 urn, and an aperture ratio of the porous membrane is from 30% to 70%.
40

WO 2018/226901 PCT7US2018/036363
6. A method of evaluating a test substance using the living tissue model device of
claim 1, the method comprising:
adding a test substance to at least one of the first liquid compartment or the second liquid compartment; and
at least one process of (i) quantifying at least one of a chemical substance contained in the first liquid compartment or a cell contained in the first liquid compartment, or (ii) quantifying at least one of a chemical substance contained in the second liquid compartment or a cell contained in the second liquid compartment.
7. The method of evaluating a test substance according to claim 6, wherein process (i) comprises quantifying at least one of a miRNA contained in the first liquid compartment, a protein contained in the first liquid compartment or a transcription factor contained in the first liquid compartment, and process (ii) comprises quantifying at least one of a miRNA contained in the second liquid compartment, a protein contained in the second liquid compartment or a transcription factor contained in the second liquid compartment.
8. The method of evaluating a test substance according to claim 6, further comprising adding a tracer to a liquid compartment to which the test substance has been added, wherein measuring an amount of the tracer that has leaked from the liquid compartment to which the tracer has been added to the other liquid compartment constitutes process (i) or (ii).
9. A vascular wall model comprising:
a porous membrane having a honeycomb structure;
a vascular endothelial cell layer disposed on one face of the porous membrane; and a smooth muscle cell layer, or a mesenchymal stem cell layer, disposed on another face of the porous membrane.
10. The vascular wall model according to claim 9, wherein a FITC-dextran 70
permeability from a vascular endothelial cell layer side to a smooth muscle cell layer side or a
mesenchymal stem cell layer side in the vascular wall model is from 0% to 10% of a
FITC-dextran 70 permeability from one face of the porous membrane to the other face of the
porous membrane.
41

WO 2018/226901 PCT7US2018/036363
11. The vascular wall model according to claim 9, wherein a material of the porous membrane comprises at least one selected from the group consisting of polybutadiene, polystyrene, polycarbonate, polysulfone, polyurethane, polylactic acid, a polylactic acid-polyglycolic acid copolymer, a polylactic acid-polycaprolactone copolymer, polyethylene terephthalate, poly(glycerol sebacate), polyacrylate, polymethacrylate, polyacrylamine, polyethylene naphthalate, polyethylene succinate, polybutylene succinate, polycaprolactone, polyamide, polyimide, a polysiloxane derivative and triacetylcellulose.
12. The vascular wall model according to claim 9, wherein each surface of the porous membrane is covered by at least one selected from the group consisting of fibronectin, collagen, laminin, vitronectin, gelatin, perlecan, nidogen, proteoglycan, osteopontin, tenascin, nephronectin, a basement membrane matrix, a recombinant peptide and polylysine.
13. The vascular wall model according to claim 9, wherein an average diameter of openings of through-holes in the porous membrane is from 1 urn to 20 urn, and an aperture ratio of the porous membrane is from 30% to 70%.
14. Avascular wall model device comprising a first liquid compartment in which a liquid composition is stored; a second liquid compartment in which a liquid composition is stored; and the vascular wall model of claim 9 disposed between the first liquid compartment and the second liquid compartment, as a partition between the first and second liquid compartments.
15. A method of evaluating a test substance using the vascular wall model device of claim 14, the method comprising:
adding a test substance to at least one of the first liquid compartment or the second liquid compartment; and
at least one process of (i) quantifying at least one of a chemical substance contained in the first liquid compartment or a cell contained in the first liquid compartment, or (ii) quantifying at least one of a chemical substance contained in the second liquid compartment or a cell contained in the second liquid compartment.
16. The method of evaluating a test substance according to claim 15, wherein process
(i) comprises quantifying at least one of a miRNA contained in the first liquid compartment, a
42

WO 2018/226901 PCT7US2018/036363
protein contained in the first liquid compartment or a transcription factor contained in the first liquid compartment, and process (ii) comprises quantifying at least one of a miRNA contained in the second liquid compartment, a protein contained in the second liquid compartment or a transcription factor contained in the second liquid compartment.
17. The method of evaluating a test substance according to claim 15, wherein one of the first liquid compartment or the second liquid compartment is a liquid compartment in which blood, a liquid composition containing erythrocytes or a liquid composition mimicking blood and containing at least one selected from the group consisting of dextran, Evans Blue, fluorescein sodium salt and FITC-microbeads is stored, the adding of a test substance to at least one of the first liquid compartment or the second liquid compartment comprises adding the test substance to the liquid compartment in which blood, a liquid composition containing erythrocytes or a liquid composition mimicking blood and containing at least one selected from the group consisting of dextran, Evans Blue, fluorescein sodium salt and FITC-microbeads is stored, and measuring at least one of an amount of erythrocytes that have leaked from the liquid compartment to which the test substance has been added to the other liquid compartment, an amount of hemoglobin that has leaked from the liquid compartment to which the test substance has been added to the other liquid compartment or an amount of at least one selected from the group consisting of dextran, Evans Blue, fluorescein sodium salt and FITC-microbeads that has leaked from the liquid compartment to which the test substance has been added to the other liquid compartment constitutes process (i) or (ii).
43